1. Home
  2. NVMI vs IONS Comparison

NVMI vs IONS Comparison

Compare NVMI & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nova Ltd.

NVMI

Nova Ltd.

N/A

Current Price

$383.08

Market Cap

12.6B

Sector

Technology

ML Signal

N/A

IONS

Ionis Pharmaceuticals Inc.

N/A

Current Price

$56.34

Market Cap

12.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NVMI
IONS
Founded
1993
1989
Country
Israel
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.6B
12.1B
IPO Year
2001
1996

Fundamental Metrics

Financial Performance
Metric
NVMI
IONS
Price
$383.08
$56.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
22
Target Price
$431.88
$93.36
AVG Volume (30 Days)
421.5K
2.1M
Earning Date
05-14-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.71
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$20.94
N/A
Revenue Next Year
$19.53
$77.99
P/E Ratio
$56.79
N/A
Revenue Growth
N/A
N/A
52 Week Low
$266.43
$50.01
52 Week High
$615.99
$86.74

Technical Indicators

Market Signals
Indicator
NVMI
IONS
Relative Strength Index (RSI) 49.88 40.32
Support Level $356.50 $50.64
Resistance Level $489.54 $57.48
Average True Range (ATR) 14.31 1.95
MACD 3.30 -0.25
Stochastic Oscillator 85.18 34.05

Price Performance

Historical Comparison
NVMI
IONS

About NVMI Nova Ltd.

Nova Ltd is a provider of metrology and process control solutions used in semiconductor manufacturing. The company provides high-performance metrology solutions across the semiconductor fabrication lifecycle and develops differentiated inline metrology solutions deployed by a broad range of customers, including integrated circuit manufacturers. Its portfolio combines high-precision hardware and software, enabling customers to improve device performance, enhance yields, and accelerate time to market. Its products include Dimensional Metrology, Materials Metrology, Chemical Metrology, and Software Solutions. The company operates in China, Taiwan, R.O.C., the United States and other regions, with maximum revenue coming from China.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Share on Social Networks: